Directors' Remuneration Policy
07 June 2020
Articles of Association
18 October 2019
Members: Julian Heslop (Chair), Ishbel Macpherson, Dr Lawson Macartney, Lisa Bright, Alison Platt and Denise Goode
Role: The Audit Committee’s key role is to review and report to the Board on financial reporting and internal financial control effectiveness, and to monitor the effectiveness of the external audit process and internal audit function.
Members: Ian Page (Chair), Paul Sandland and Melanie Hall
Role: The Disclosure Committee’s key role is to develop and maintain adequate procedures, systems and controls to comply with the Company’s obligations regarding identification and disclosure of inside information.
Members: Tony Rice (Chair), Julian Heslop, Ishbel Macpherson, Dr Lawson Macartney, Lisa Bright, Alison Platt and Denise Goode
Role: The purpose of the Nomination Committee is to lead the appointment process, satisfy itself that plans are in place for orderly succession for appointments to the Board and Senior management, and oversee the development of a diverse pipeline for succession.
Members: Ishbel Macpherson (Chair), Tony Rice, Julian Heslop, Dr Lawson Macartney, Lisa Bright, Alison Platt and Denise Goode
Role: The Remuneration Committee’s key role is to determine remuneration policies, that are designed to support strategy and promote long term sustainable success, and set the remuneration of the Company’s Chairman, Executive Directors and Senior Executive Team.
Our Executive Directors’ pay continues to be implemented in accordance with the Remuneration Policy approved by the shareholders at the 2020 AGM.
The beneficial interests of the Directors in office and their families in the share capital of Dechra Pharmaceuticals PLC are as follows:
|Director||As at 30 September 2021|
|Number of Ordinary Shares||Percentage of issued share capital|
Section 172 Statements
The Companies (Miscellaneous Reporting) Regulations 2018 require Dechra Pharmaceuticals PLC and one of its subsidiaries to publish a statement explaining how the Directors have given due regard for the matters set out in section 172 (1) (a) to (f) of the Companies Act 2006 while performing their duty to promote the success of the Company for the benefit of its members as a whole (section 172 statement).
Below is the section 172 statement for the Group's subsidiary captured by these Regulations.